Abstract WP232: ICH Time To Treatment: A Retrospective Review

Background: Approximately 80,000 Americans have a spontaneous ICH every year. ICH is the deadliest type of acute stroke and disproportionately affects lower resourced populations. The AHA/ASA released a revised ICH guideline in 2022 and Expanded GWTG Stroke adding additional ICH data elements in 2023. Soon after, facilities were invited to join a pilot abstraction with new ICH stroke performance measures, and we were among the first to participate. The guidelines and data elements highlight the need for blood pressure control and anticoagulant reversal quickly for this critical patient population. Method: The method applied was a retrospective review of ICH patients’ blood pressure control and reversal times in a CSC within a mid-sized city in the Southeastern United States. The period included in this review was a sample of ICH patients from January 2024 to December 2024. Review consisted of door to antihypertensive agent timing, type of antihypertensive medication administered, door to reversal agent timing, and the timeliness of patients to a sustained BP